What Is the FDA's Draft Peptide "Interim Access Policy" Now Under White House Review?
TL;DR:: FDA sent a draft peptide "interim access policy" to OMB on 14 Oct 2026. Its text is unpublished, and it is US compounding policy, not a drug approval.
What Did FDA Send to the White House on 14 October 2026?
On 14 October 2026 HHS and the FDA sent a draft notice titled "Interim Access Policy for Compounding Using Certain Peptides" to the Office of Management and Budget (OMB) for review. The federal regulatory dashboard lists it under identifier RIN 0910-ZD94 as pending review, with no legal deadline, and publishes no policy text.[1] Reuters-syndicated and STAT reporting on 15 October described it as a step toward letting pharmacies temporarily compound certain widely discussed peptides, BPC-157 among them.[2][3]
Everything beyond that headline is unconfirmed. We could not retrieve the primary OMB page from our publishing environment, so readers should check the listing directly at reginfo.gov before relying on any detail here.
What Is Enforcement Discretion, and How Is It Different From a Bulks-List Decision?
Law-firm analysis of the filing says the policy would work through enforcement discretion: the agency signalling that, for a defined interim period, it does not intend to take action over certain compounding activity.[4] That differs from adding a substance to the Section 503A bulk drug substances list, which requires rulemaking and several rounds of public comment and can take years.[4] It also differs from a marketing approval, which rests on a sponsor's safety and efficacy dossier. Our guide to FDA peptide reclassification sets out how these pathways interact.
| Mechanism | What it does | Needs rulemaking? |
|---|---|---|
| Marketing approval | Authorises a sponsor's product after review of trial data | No (application process) |
| 503A bulks list | Permits named substances to be compounded under statutory conditions | Yes |
| Enforcement discretion | Agency states it will not prioritise enforcement for a period | No; can be withdrawn |
How Does This Relate to the July 2026 Advisory Committee Votes?
In July the FDA's Pharmacy Compounding Advisory Committee recommended six of seven peptides under review for the 503A list, including BPC-157, KPV, TB-500 and MOTS-c, and declined DSIP. Our write-up is in the PCAC vote outcome guide. Advisory votes are non-binding, and the formal listing route remains slow. A press summary of the October filing frames the interim policy as a faster, temporary alternative to that route.[4][5] Whether the interim policy would track the committee's list is not known.
What Remains Unknown?
Scope
Which peptides, and whether the list matches the July committee recommendations, is unpublished.
Conditions
Quality, sourcing and labelling conditions, and any end date, are not public.
Timing
OMB review carries no legal deadline, so release could be days or months away.
Durability
Discretion can be withdrawn or challenged, unlike a final rule.
Does a US Policy Change UK Research-Reagent Rules?
No. The 503A framework governs US pharmacies preparing compounded drugs. UK supply of research reagents sits under separate law and MHRA guidance; see are research peptides legal in the UK? and the 503B comment-period guide for a parallel US docket. Keep three categories apart: licensed pharmaceutical development, US regulatory process, and research-use compounds handled in vitro under a supplier's certificate of analysis. A policy move in the second does not alter the third. Researchers can review the reagent for BPC-157 on its product page.
Compounds are supplied by Velox Peptides as research reagents only. They are not medicines and have not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- Office of Information and Regulatory Affairs. RIN 0910-ZD94, FDA/HHS "Interim Access Policy for Compounding Using Certain Peptides", received 14 October 2026. reginfo.gov
- STAT News. Report on the administration advancing a peptide plan, 15 October 2026. statnews.com
- "US FDA takes step to change peptide compounding policy" (Reuters syndication), 15 October 2026. wmbdradio.com
- Holland & Knight. "Peptides at a Crossroads: What Wellness Providers Need to Know", 16 October 2026. hklaw.com
- American Med Spa Association. "FDA Sends Peptide 'Interim Access Policy' to White House for Review", October 2026. americanmedspa.org
Frequently Asked Questions
What did FDA send to the White House on 14 October 2026?
A draft notice titled "Interim Access Policy for Compounding Using Certain Peptides" (RIN 0910-ZD94) was received for review by the Office of Management and Budget on 14 October 2026. The OMB listing shows it as pending review and does not publish the policy text.
Is the interim access policy in force?
No. As of 23 October 2026 it has not been issued, and its contents are not public. Reporting indicates it would operate through enforcement discretion, but that has not been confirmed in a published document.
Is enforcement discretion the same as adding peptides to the 503A bulks list?
No. Enforcement discretion is an agency choosing, for a period, not to enforce certain requirements. Adding a substance to the 503A bulks list is a separate process that requires rulemaking and public comment. Neither is a drug approval.
Does this change the position for UK research reagents?
No. This is a US policy on pharmacy compounding. UK research-reagent supply is governed by separate law and MHRA guidance, and Velox Peptides supplies compounds as in vitro research reagents only.
Which peptides would the policy cover?
Unknown. The text is unpublished. Press reports mention BPC-157 as an example, and the FDA advisory committee reviewed seven peptides in July 2026, but the actual scope can only be confirmed when the document is released.